Drug Abuse Aspects of HIV/AIDS and Other Infections (R21)

The summary for the Drug Abuse Aspects of HIV/AIDS and Other Infections (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Drug Abuse Aspects of HIV/AIDS and Other Infections (R21): This Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), is intended to support Exploratory/Developmental research projects that address drug abuse aspects of HIV/AIDS, other blood-borne and sexually transmitted infections, and TB in men and women, adolescents and adults, and in majority and minority populations.

Federal Grant Title:	Drug Abuse Aspects of HIV/AIDS and Other Infections (R21)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health Education
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PA-06-309
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse Research Programs
Current Application Deadline:	No deadline provided
Original Application Deadline:	Multiple Receipt Dates - See Link to Full Announce
Posted Date:	Mar 31, 2006
Creation Date:	Mar 31, 2006
Archive Date:	Nov 09, 2006
Total Program Funding:
Maximum Federal Grant Award:	$200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Native American tribal organizations (other than Federally recognized tribal governments) County governments City or township governments Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) State governments Native American tribal governments (Federally recognized) Private institutions of higher education Independent school districts For profit organizations other than small businesses
Additional Information on Eligibility: Foreign institutions are eligible to apply. Eligible agencies of the Federal Government are eligible to apply.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...